DogStem

At EquiCord we have been developing DogStem since 2017: our product for the treatment of canine osteoarthritis. We’re expecting DogStem to be on the market in 2022.

"Osteoarthritis is one of the most common pathologies in adult and geriatric dogs with an incidence of between 20% and 80% in elderly dogs and the most common cause of lameness in dogs older than one year"

(Cabon et al. 2019)

Osteoarthritis in dogs causes chronic pain and a substantial loss in the quality of life of the animals. Unfortunately, despite an estimated more than 40 million dogs in the EU are affected by osteoarthritis, conventional treatments are limited to the systemic administration of anti-inflammatory drugs. These anti-inflammatories, although increasingly specific, safety and effectiveness, when applied chronically are associated with potentially serious side effects (gastric ulcer, kidney failure, liver disease, etc.).

The development of stem cells based medicines at a competitive price in this type of pathology will mean a therapeutic revolution for our pets.

Preclinical

Preclinical 100%

Collection of safety and efficacy data in the intra-articular use of autologous mesenchymal stem cells in dogs with Osteoarthritis

Phase I

Safety 100%

Single and repeated dose

*VICH GL9

Immunogenicity clinical trial: Cellular and Humoral response

*VICH GL9

Phase II

Exploratory 100%

Exploratory study of safety and efficacy in canine osteoarthritis (OA) treated with mesenchymal stem cells versus placebo in pilot animals

*VICH GL9

Phase III

Confirmatory 100%

Confirmatory clinical trial of safety and efficacy in the use of DogStem in dogs with mild to severe osteoarthritis (OA) under field conditions

*VICH GL9